AltMountain

Pavaki Capital Management, LLC

Location not listed · CRD 316395
Hedge fund manager

Pavaki Capital Management, LLC is an SEC-registered investment adviser that reports managing 1 hedge fund on Form ADV. It reports $410.1 million in regulatory assets under management. Its private funds, of all types, hold $410.1 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +0.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +0.1% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.

Regulatory assets under management
$410.1 millionForm ADV Item 5.F
Gross assets of private funds
$410.1 millionAll private fund types, Form ADV
Hedge funds managed
11 private funds in total
Employees
6Form ADV Item 5.A
Registration
SEC-registered adviserCRD 316395
Latest Form ADV
08/06/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+0.1%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 quarters+0.1%Q1 2026 – Q2 2026
S&P 500+9.5%Same quarters, price only
13F holdings$175.5 million132 positions, 2026-06-30
$91$100$110Q1 2026Q2 202613F est. $100S&P 500 $110
QuarterEst. 13F returnS&P 500
Q2 2026+10.5%+14.8%
Q1 2026-9.4%-4.6%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 132 share positions ($199,865,864) reported by Pavaki Capital Management LLC on Form 13F for the quarter ended Sep 30, 2026, filed Oct 26, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Nvidia Corporation14.85%
  • Chevron Corporation10.52%
  • Intuit5.32%
  • Barrick MNG Corp4.61%
  • Qualcomm Inc4.51%
  • Regeneron Pharmaceuticals4.29%
  • Milestone Pharmaceuticals In4.04%
  • Textron Inc3.46%
  • B2gold Corp3.08%
  • Arcutis Biotherapeutics Inc2.47%
StockValue% of 13F portfolioSharesShares vs prior quarter
Nvidia Corporation$29,689,40014.85%130,000+400.00%
Chevron Corporation$21,033,63010.52%103,000+6.19%
Intuit$10,642,4065.32%38,600Unchanged
Barrick MNG Corp$9,211,1654.61%226,500+2.26%
Qualcomm Inc$9,017,9604.51%49,000Unchanged
Regeneron Pharmaceuticals$8,568,4514.29%11,300+14.14%
Milestone Pharmaceuticals In$8,083,7754.04%9,337,848+2.98%
Textron Inc$6,918,9603.46%90,800+7.71%
B2gold Corp$6,159,9523.08%1,180,000Unchanged
Arcutis Biotherapeutics Inc$4,942,4102.47%187,000Unchanged
Micron Technology Inc$4,260,4402.13%4,000Unchanged
Centerra Gold Inc$3,856,1231.93%177,000-10.15%
Newmont Corp$3,748,5501.88%32,500Unchanged
Ligand Pharmaceuticals Inc$3,467,3071.73%11,100Unchanged
SLB Limited$2,971,9201.49%61,000Unchanged
Harmony Biosciences Hldgs In$2,865,9801.43%73,000Unchanged
Ars Pharmaceuticals Inc$2,842,8761.42%659,600-24.13%
Royalty Pharma PLC$2,567,8401.28%44,000Unchanged
Bio Rad Labs Inc$2,266,2601.13%6,000Unchanged
Paramount Skydance Corp$2,157,5611.08%208,863Unchanged
Ishares Inc$1,995,6001.00%60,000Unchanged
FS KKR Cap Corp$1,979,2990.99%180,100+12.49%
SSR Mining In$1,766,2540.88%53,000-29.33%
Newamsterdam Pharma Company$1,619,7120.81%66,600Unchanged
Douglas Elliman Inc$1,554,2790.78%1,022,552Unchanged
Halliburton Co$1,462,8000.73%46,000Unchanged
Ishares TR$1,318,9200.66%58,000Unchanged
Yum China Hldgs Inc$1,233,0000.62%30,000Unchanged
Kinross Gold Corp$1,192,6980.60%49,500Unchanged
Baidu Inc$1,129,3100.56%13,000Unchanged
Syndax Pharmaceuticals Inc$1,128,0000.56%60,000Unchanged
Oceanagold Corp$1,106,9500.55%40,200Unchanged
Equinox Gold Corp$1,010,7900.51%91,000-9.00%
RMR Group Inc$1,003,4400.50%55,500+56.34%
Banco Bradesco S A$930,4630.47%264,336Unchanged
Ubs Group AG$915,9330.46%19,000Unchanged
Telefonaktiebolaget LM Erics$892,1250.45%97,500Unchanged
Royal Gold Inc$885,0000.44%3,750Unchanged
Orasure Technologies Inc$858,6090.43%219,033Unchanged
Icon Pub LTD Co$849,9500.43%5,000Unchanged
Sanofi SA$824,6000.41%20,000Unchanged
Baker Hughes Company$823,5000.41%15,000Unchanged
Kaspi KZ JSC$818,3220.41%8,700Unchanged
Biogen Inc$790,5800.40%3,500Unchanged
Merck & Co Inc$726,5500.36%5,000Unchanged
Lantheus Hldgs Inc$706,6630.35%7,100Unchanged
KBR Inc$703,2000.35%20,000Unchanged
Itau Unibanco Hldg S A$702,8720.35%82,400Unchanged
Cellebrite Di LTD$675,6000.34%60,000Unchanged
Diversified Healthcare TR$667,2500.33%85,000Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 9 new positions, 9 sold out, 9 increased, 5 reduced and 109 unchanged.

Number of positions (a count, not dollars)

  • New positions9
  • Increased9
  • Unchanged109
  • Reduced5
  • Sold out9

New positions

StockValueShares
Caris Life Sciences Inc$612,60020,000
Real Remax Group Inc$210,63512,875
Huntington Ingalls Inds Inc$186,949700
Nuvectis Pharma Inc$158,4007,500
Honeywell Aerospace Inc$154,9701,000
Genelux Corporation$151,80060,000
Odyssey Therapeutics Inc$111,1005,000
Eikon Therapeutics Inc$80,40010,000
Wave Life Sciences Inc.$55,50015,000

Sold out

StockValue at Jun 30, 2026Shares held then
Advanced Micro Devices Inc$2,323,6404,000
Nokia Corp$929,60070,000
Replimune Group Inc$890,02880,400
Intel Corp$558,5204,000
Aris Mining Corporation$447,30030,000
Catalyst Pharmaceuticals Inc$251,4408,000
Re/max Hldgs Inc$246,50025,000
Pebblebrook Hotel TR$232,92012,000
Wave Life Sciences LTD$87,15015,000

Largest increases

StockChange in sharesChangeValue nowShares now
Nvidia Corporation+104,000+400.00%$29,689,400130,000
Chevron Corporation+6,000+6.19%$21,033,630103,000
Regeneron Pharmaceuticals+1,400+14.14%$8,568,45111,300
Textron Inc+6,500+7.71%$6,918,96090,800
RMR Group Inc+20,000+56.34%$1,003,44055,500
Milestone Pharmaceuticals In+270,000+2.98%$8,083,7759,337,848
FS KKR Cap Corp+20,000+12.49%$1,979,299180,100
Barrick MNG Corp+5,000+2.26%$9,211,165226,500
Novo-nordisk A S+5,000+111.11%$360,1459,500

Largest reductions

StockChange in sharesChangeValue nowShares now
Ars Pharmaceuticals Inc-209,800-24.13%$2,842,876659,600
SSR Mining In-22,000-29.33%$1,766,25453,000
Centerra Gold Inc-20,000-10.15%$3,856,123177,000
Silvercorp Metals Inc-30,000-60.00%$213,40020,000
Equinox Gold Corp-9,000-9.00%$1,010,79091,000

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Milestone Pharmaceuticals Inc.13G7.3%9,067,848Aug 7, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Aug 7, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (1)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (1)

Fund
Gross assets
Minimum
Owners
Adviser
Pavaki Capital Partners, LP
Delaware, United StatesHedge fund
Gross assets$37.6M
Minimum$1.0M
Owners1
AdviserPavaki Capital Management, LLC

As reported in the adviser's Form ADV filed Mar 4, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌‌⁠